The analgesia, anti-cold medicine and vasodilator markets contributed to the growth of this sector in 2012.
If the prescription drug market looks gray (-2.4% in 2012), the self-medication market underwent a vitamin cure last year. It increased by 2.4%, according to the barometer of the French Association of the pharmaceutical industry for responsible self-medication (Afipa).
In the hit parade of the strongest growth we find the antalgia market (+ 5.1%) and that of the respiratory tract (+ 3.3%). That of circulation increased by + 10.9% due in particular to the delisting of vasodilators.
The market for medical accessories and devices, not subject to prescriptions, and that of food supplements are also experiencing, according to Afipa, “major growth” with respectively + 4.3% and + 5.9%.
For Afipa, “this dynamism shows that self-medication is gradually establishing itself as a basic trend sought by patients concerned with being an actor in their health …” However, representatives of the profession note that “the France still shows a major delay compared to other European countries “. And call for “strong political initiatives”.
The Top 10 contributions to
the growth of self-medication in 2012
1- Doliprane
2- Tanakan
3- Berroca
4- Humex
5- Oscillococinum
6- Titanoreine
7- Alodont
8- Rhinadvil
9- Mycolydralin
10- Fervex
Source Afipa
.
